Abstract Number: 0125 • ACR Convergence 2023
Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis
Background/Purpose: Patients with lupus nephritis may die of active systemic lupus erythematosus (SLE) disease, end-stage renal disease (ESRD) and its complications as well as of…Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…Abstract Number: 1056 • ACR Convergence 2023
Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…Abstract Number: 1058 • ACR Convergence 2023
Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…Abstract Number: 1074 • ACR Convergence 2023
Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting
Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience
Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…